AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JANUARY 14, 2002
REGISTRATION NO. 333-______
===============================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
---------------------------------
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
----------
TRIANGLE PHARMACEUTICALS, INC.
(Exact name of Registrant as Specified in Its Charter)
Delaware 56-1930728
(State or Other Jurisdiction of (I.R.S. Employer
Incorporation or Organization) Identification No.)
----------
4 University Place,
4611 University Drive,
Durham, North Carolina, 27707
(919) 493-5980
(Address, Including Zip Code, And Telephone Number, Including Area Code,
Of Registrant's Principal Executive Offices)
----------
Triangle Pharmaceuticals, Inc.
1996 Stock Incentive Plan
(Full Title of the Plans)
----------
David W. Barry, M.D.
Chairman and Chief Executive Officer
TRIANGLE PHARMACEUTICALS, INC.
4 University Place,
4611 University Drive,
Durham, North Carolina 27707
(919) 493-5980
(Name, Address, Including Zip Code, and Telephone Number, Including Area Code,
of Agent For Service)
----------
CALCULATION OF REGISTRATION FEE
---------------------------------------------------------------------------------------------------------------------------
PROPOSED MAXIMUM PROPOSED MAXIMUM AMOUNT OF
TITLE OF SECURITIES TO BE AMOUNT TO BE OFFERING PRICE PER AGGREGATE OFFERING PRICE REGISTRATION
REGISTERED REGISTERED (1) SHARE (2) (2) FEE
===========================================================================================================================
Common Stock, $0.001 par 1,500,000 shares $4.18 $6,270,000 $1,499
value per share
---------------------------------------------------------------------------------------------------------------------------
(1) This Registration Statement shall also cover any additional shares of Common
Stock which become issuable under the Triangle Pharmaceuticals, Inc. 1996 Stock
Incentive Plan by reason of any stock dividend, stock split, recapitalization or
other similar transaction effected without Registrant's receipt of consideration
which results in an increase in the number of the outstanding shares of
Registrant's Common Stock.
(2) Calculated solely for purposes of this offering under Rule 457(h) of the
Securities Act of 1933, as amended, on the basis of the average of the high and
low selling prices per share of the Registrant's Common Stock on January 11,
2002, as reported by the Nasdaq National Market.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE
This Registration Statement on Form S-8 (the "Registration Statement")
relates to the registration of an additional 1,500,000 shares (the "Shares") of
Common Stock, $.001 par value, of the Registrant. The Shares are securities of
the same class and relating to the same employee benefit plan, the Triangle
Pharmaceuticals, Inc. 1996 Stock Incentive Plan, as those shares registered in
the Registrant's Registration Statements on Form S-8, previously filed with the
Securities and Exchange Commission on June 5, 1998 (Registration No. 333-56189),
March 22, 1999 (Registration No. 333-74805), January 14, 2000 (Registration No.
333-94725) and January 31, 2001 (Registration No. 333-54696). The earlier
Registration Statements on Form S-8 are hereby incorporated by reference.
The financial statements contained in the Registrant's Annual Report on
Form 10-K for the year ended December 31, 2000 are incorporated by reference in
this Registration Statement and have been so incorporated in reliance on the
report of PricewaterhouseCoopers LLP, independent accountants, given on the
authority of said firm as experts in auditing and accounting.
The following additional documents are incorporated by reference in this
registration statement:
1. Our Quarterly Report on Form 10-Q for the quarterly period
ended March 31, 2001 filed on May 10, 2001;
2. Our Quarterly Report on Form 10-Q for the quarterly period
ended June 30, 2001 filed on August 13, 2001;
3. Our Quarterly Report on Form 10-Q for the quarterly period
ended September 30, 2001 filed on November 9, 2001;
4. Our Annual Report on Form 10-K for the fiscal year ended
December 31, 2000 filed on February 26, 2001, including
information in our Definitive Proxy Statement in connection
with our 2001 Annual Meeting of Stockholders;
5. Our Current Reports on Form 8-K filed March 21, 2001,
August 7, 2001, August 10, 2001, August 24, 2001,
October 10, 2001 and December 7, 2001; and
6. The description of our common stock contained in our
Registration Statements on Form 8-A filed October 18, 1996,
February 10, 1999, June 18, 1999 and August 24, 2001.
II-1
All documents filed by the Company pursuant to Sections 13(a), 13(c),
14 and 15(d) of the Securities and Exchange Act of 1934, as amended (the
"Exchange Act") on or after the date of this Registration Statement and prior to
the filing of a post-effective amendment which indicates that all securities
offered have been sold or which deregisters all securities then remaining unsold
shall be deemed to be incorporated by reference in this Registration Statement
and to be part hereof from the date of filing of such documents.
ITEM 8. EXHIBITS
NUMBER EXHIBIT
------ -------
5 Opinion and consent of Smith, Anderson, Blount, Dorsett,
Mitchell & Jernigan, L.L.P.
23.1 Consent of PricewaterhouseCoopers LLP, Independent
Accountants.
23.2 Consent of Smith, Anderson, Blount, Dorsett, Mitchell &
Jernigan, L.L.P. is contained in Exhibit 5.
24 Power of Attorney. Reference is made to pages II-3 and II-4 of
this Registration Statement.
II-2
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended,
the Registrant certifies that it has reasonable grounds to believe that it meets
all of the requirements for filing on Form S-8, and has duly caused this
Registration Statement to be signed on its behalf by the undersigned, thereunto
duly authorized, in the City of Durham, State of North Carolina on this 14th day
of January, 2002.
TRIANGLE PHARMACEUTICALS, INC.
By: /s/ David W. Barry
--------------------------
David W. Barry
Chairman and Chief Executive Officer
and Director
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS:
That the undersigned officers and directors of Triangle
Pharmaceuticals, Inc., a Delaware corporation, do hereby constitute and appoint
David W. Barry and Chris A. Rallis and each one of them, the lawful
attorneys-in-fact and agents with full power and authority to do any and all
acts and things and to execute any and all instruments which said attorneys and
agents, and any one of them, determine may be necessary or advisable or required
to enable said corporation to comply with the Securities Act of 1933, as
amended, and any rules or regulations or requirements of the Securities and
Exchange Commission in connection with this Registration Statement. Without
limiting the generality of the foregoing power and authority, the powers granted
include the power and authority to sign the names of the undersigned officers
and directors in the capacities indicated below to this Registration Statement,
to any and all amendments, both pre-effective and post-effective, and
supplements to this Registration Statement, and to any and all instruments or
documents filed as part of or in conjunction with this Registration Statement or
amendments or supplements thereof, and each of the undersigned hereby ratifies
and confirms all that said attorneys and agents, or any one of them, shall do or
cause to be done by virtue hereof. This Power of Attorney may be signed in
several counterparts.
IN WITNESS WHEREOF, each of the undersigned has executed this Power of
Attorney as of the date indicated.
Pursuant to the requirements of the Securities Act of 1933, as amended,
this Registration Statement has been signed below by the following persons in
the capacities and on the dates indicated.
II-3
SIGNATURE TITLE
--------- -----
/s/ David W. Barry Chairman of the Board and Chief Executive Officer January 14, 2002
--------------------------------------- (Principal Executive Officer)
David W. Barry
/s/ Chris A. Rallis Director, President and Chief Operating Officer January 14, 2002
---------------------------------------
Chris A. Rallis
/s/ Robert F. Amundsen, Jr. Executive Vice President and Chief Financial January 14, 2002
--------------------------------------- Officer (Principal Financial and Accounting
Robert F. Amundsen, Jr. Officer)
/s/ Anthony B. Evnin Director January 14, 2002
---------------------------------------
Anthony B. Evnin
/s/ Standish M. Fleming Director January 14, 2002
---------------------------------------
Standish M. Fleming
/s/ Dennis B. Gillings Director January 14, 2002
---------------------------------------
Dennis B. Gillings
/s/ Henry G. Grabowski Director January 14, 2002
---------------------------------------
Henry G. Grabowski
/s/ Stewart J. Hen Director January 14, 2002
---------------------------------------
Stewart J. Hen
/s/ Jonathan S. Leff Director January 14, 2002
---------------------------------------
Jonathan S. Leff
/s/ George McFadden Director January 14, 2002
---------------------------------------
George McFadden
/s/ James L. Tyree Director January 14, 2002
---------------------------------------
James L. Tyree
II-4
EXHIBIT INDEX
NUMBER EXHIBIT
------ -------
5 Opinion and consent of Smith, Anderson, Blount, Dorsett,
Mitchell & Jernigan, L.L.P..
23.1 Consent of PricewaterhouseCoopers LLP, Independent
Accountants.
23.2 Consent of Smith, Anderson, Blount, Dorsett, Mitchell &
Jernigan, L.L.P. is contained in Exhibit 5.
24 Power of Attorney. Reference is made to pages II-3 and II-4 of
this Registration Statement.